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Abstract  
 
Background: There are still no effective treatments for superficial bladder cancer / 
non-muscle invasive bladder cancer (SBC/NMIBC). Following treatment 20% of 
patients still develop metastatic disease. SBC is often multifocal, has high recurrences 
after surgical resection and recurs after intravesical live BCG. OncovexGALV/CD, an 
oncolytic HSV-1, has shown enhanced local tumour control by combining oncolysis 
with the expression of a highly potent pro-drug activating gene and the fusogenic 
glycoprotein.  
Methods: In vitro fusion/prodrug/apoptotic cell based assays In vivo orthotopic 
bladder tumour model, visualised by micro CT. 
Results: Treatment of seven human bladder carcinoma cell lines with the virus 
resulted in tumour cell killing through oncolysis, pro-drug activation and glycoprotein 
fusion. OncovexGALV/CD and mitomycin C showed a synergistic effect, whereas the 
co-administration with cisplatin or gemcitabine showed an antagonistic effect in vitro. 
transitional cell cancer (TCC) cells follow an apoptotic cell death pathway after 
infection with OncovexGALV/CD with or without 5-FC. In vivo results showed that 
intravesical treatment with OncovexGALV/CD + prodrug (5-FC) reduced the average 
tumour volume by over 95% compared to controls.  
Discussion: Our in vitro and in vivo results indicate that OncovexGALV/CD can improve 
local tumour control within the bladder, and potentially alter its natural history.  
 3 
Introduction  
 
Bladder cancer is the fourth most common malignancy in men, with an estimated 
70,530 new cases and 14,680 deaths in the USA in 2010 (www.cancer.gov). 
Approximately 70% of these patients initially present with superficial bladder cancer 
(SBC) (Kirkali et al, 2005). The standard treatment for patients with SBC is 
transurethral resection of the bladder tumor (TURBT), followed by adjuvant 
intravesical instillations with chemotherapy and/or immunotherapy BCG (bacillus 
Calmette-Guérin). The probabilities of recurrence and progression in non muscle 
invasive bladder cancer at 5 years after standard treatment range from 31% to 78% 
(Sylvester et al, 2006). These rates illustrate the modest success of currently available 
treatments and underline the need for improved therapies. 
 
Oncolytic HSV vectors have shown promising efficacy against a wide variety of 
malignancies, both in vitro and in vivo and clinical trials for patients with metastatic 
colorectal, head and neck, breast, and prostate cancer, melanoma, and glioma have 
been completed (Kasuya et al, 2005). OncovexGALV/CD is a third generation oncolytic 
herpes simplex virus 1 (HSV-1) that combines oncolysis with the expression of a 
highly potent pro-drug activating gene (yeast cytosine deaminase/uracil phospho-
ribosyltransferase fusion [Fcy::Fur]) and the fusogenic glycoprotein from gibbon ape 
leukemia virus (GALV). ICP34.5 deletion within the backbone of OncovexGALV/CD 
result in tumour selective viral replication (Liu BL et al, 2003). In addition a deletion 
of ICP47 increases the antitumor immune response in the presence of HSV and places 
the Us11 gene under immediate-early promoter control, which enhances growth of 
HSV ICP34.5 mutants in tumour cells (Liu BL et al, 2003). Previous studies with 
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OncovexGALV/CD have shown enhanced cell killing and tumour shrinkage (in vitro and 
in vivo) within tumours derived from head (and neck), colon, pancreas, lung and 
glioma tissue (Simpson et al, 2006; Price et al, 2010; Wong et al, 2010). A version of 
this virus expressing GM-CSF has also shown promising results in clinical phase I-II 
trials (Hu et al, 2006; Kaufman et al, 2010) and is currently in clinical phase III for the 
treatment of melanoma and head and neck.  
 
Bladder cancer is potentially an ideal tumour model for novel therapies because 
intravesical delivery is able to expose the tumour to high concentrations of virus. In 
addition, the umbrella cell layer (i.e., the luminal surface of the urothelium) of the 
bladder is not rapidly dividing and should therefore be resistant to infection and lysis 
by replication-competent oncolytic viruses, which selectively infect and replicate 
within rapidly dividing cells. Therefore we studied the effect of OncovexGALV/CD in 
combination with 5-FC/chemo agents on bladder malignancies in vitro and in vivo in 
an orthotopic rat bladder cancer model.  
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Materials and Methods 
 
Viruses and cell lines.  
 
The viruses used in the study were previously described by Simpson et al 2005 and 
constructed. OncovexGFP (backbone virus) and OncovexGALV/CD stocks were supplied 
by BioVex Inc. (34 Commerce way, Woburn, MA, 01801, USA). Human bladder 
carcinoma cells (EJ, T24, RT112) and baby hamster normal kidney cells (BHK-21) 
were purchased from American Tissue Culture Collection (ATCC). Other human 
bladder carcinoma cells (VMVUB-I, TCCSUP-G, 5637, KU19-19) were kindly given 
by Professor Margaret Knowles (Cancer Research UK Clinical Centre, Leeds). The 
rat bladder carcinoma cell line (AY-27) was kindly given by Dr. Ronald B. Moore 
(University of Alberta). 
 
Fusion assay.  
 
The TCC cells were infected with OncovexGALV/CD or OncovexGFP at MOI between 
10-0.0001 and incubated at 37°C for 48 hours. Cells were then either fixed and 
stained with Glutaraldehyde, Crystal Violet, (Sigma St. Louis, MO) or treated with 
MTS reagent (Promega, Madison, WI ). 
 
Prodrug-activating assay.  
 
The TCC cells were infected with OncovexGALV/CD or OncovexGFP at MOI between 1-
0.01. After 30 minutes at 37°C/5% CO2, the virus was removed, and full growth 
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media containing 5-FC (C4H4FN2O; Sigma, St. Louis, MO) was added and incubated 
for 48 hours at 37°C/5% CO2. The cell supernatant was transferred into a fresh tube, 
and the cell debris was removed by centrifuging. The supernatants were added to a 
fresh tube and heat and activated at 60°C for 10 minutes. The resulting supernatants 
were allowed to cool to room temperature and added to test cells. Cells were then 
either fixed and stained using Glutaraldehyde, Crystal Violet, (Sigma,St. Louis, MO) 
or treated with MTS reagent (Promega, Madison, WI ).  
 
In vitro synergy assay.  
 
The effect of combination of agents on cell proliferation was assessed by calculating 
combination index (CI) values using CalcuSyn software (Biosoft). Derived from the 
median-effect principal of Chou and Talalay the CI provides a quantitative measure of 
the degree of interaction between two agents. A CI of 1 denotes an additive 
interaction, >1 antagonism, and <1 synergy. Experiments were done as described for 
the in vitro survival assay using 4, 2, 1, 0.5, and 0.25 times the calculated ED50 of each 
agent in a constant ratio checkerboard design.  
 
Determination of cell death.  
 
Caspase 3 and 7 activity was detected on EJ cells which were infected with either 
OncovexGALV/CD or OncovexGFP (with or without 5-FC/5-FC metabolites) by Caspase 
Glo 3/7 reagent (Promega, Madison, WI). Apoptotic Z-VAD fmk inhibiter (50uM) 
and Necrosis inhibiter (20mM) Fructose was obtained from Sigma.  
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Orthotopic rat bladder tumour model.  
 
All procedures were approved by United Kingdom Home Office. Fischer F344 female 
rats were purchased from B&K Universal or Harlan Ltd. The animals were placed in a 
supine position and were anesthetised with Isoflurane. The catheter (18-gauge BD 
Venflon TM) was inserted into the bladder via the urethra. To facilitate the tumour 
seeding the bladder mucosa was damaged by instillation 0.1 N hydrochloric acid 
followed by a rinse with 0.1N sodium hydroxide for neutralization. The bladder was 
washed five times with PBS. A suspension of freshly harvested AY-27 HVEM cells 
(1.5-2.5x106 cells) was then instilled and maintained in the bladder for 1 hour. After 1 
hour the catheters were removed, and the rats were allowed to void spontaneously.  
Immunohistochemistry for Ki67 
 
Paraffin sections were cut at 4 µm, dewaxed, and rehydrated before being subjected to 
heat-mediated antigen retrieval in a microwave using citrate buffer (10mM, pH6.0). 
Ki67 (ab16667, Abcam) was diluted 1:100 in 1% BSA in PBS and incubated on the 
sections overnight at room temperature in a humidity chamber. The bound primary 
antibody was detected using the Vectastain Elite ABC peroxidase system kit 
(VECTOR laboratories, Burlingame, CA, USA) followed by DAB detection (DAKO, 
Denmark). To test the specificity of immunostaining the primary antibody was 
omitted. Under this condition no staining was identified. 
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Results 
 
Human bladder TCC cell lines are sensitive to viral HSV oncolysis, which is 
enhanced by the expression of GALV glycoprotein.  
 
A panel of 7 TCC cell lines were tested for viral HSV oncolysis. High viral 
replication of the oncolytic HSV (OncovexGALV/CD) was observed in all 7 TCC cell 
lines with viral plaque detected as low as 0.1-0.001 MOI. This HSV viral replication 
led to a strong tumour cytotoxcity effect which was detected by MTS assay at an moi 
as low as 0.001 (data not shown). The expression of GALV glycoproteins enhanced 
this viral tumour selective killing in four out of the seven TCC cell lines infected with 
OncovexGALV/CD. GALV expression led to the formation of multinucleated syncytia 
which were then surrounded with cells showing the more classic HSV-1-mediated 
effect, (EJ cells, T24 cells, VMCUB-I cells, and 5637 cells) (Figure 1a). To study 
whether the formation of multinucleated syncytia increased the cytopathic effect of 
this virus (OncovexGALV/CD) when compared to the backbone virus (OncovexGFP) in 
vitro MTS assays were carried out. Lower levels of MTS activity were seen with 
OncoVEXGALV/CD than OncovexGFP on infected EJ (42-54% decrease in cell survival, 
P<0.000), T24 (35-45%, P<0.000), VMCUB-I (36-37%, P<0.000) and 5637 (35% 
P<0.000) cells. This suggests that the presence of GALV env R- increased tumour cell 
killing (Figure 1b).  
 
Fcy::Fur expression converts 5-FC to 5-FU metabolites within human bladder 
TCC cell lines in vitro.  
 9 
Fcy::Fur is a fusion of two yeast genes CD and UPRT, which metabolizes 5-FC more 
efficiently than either gene alone. To study the cell killing effects of 5-FC metabolites 
on TCC cells we infected human EJ cells with OncovexGALV/CD or OncovexGFP in the 
presence or absence of 5-FC for 48hrs at 370C. The cell supernatants were then heat 
inactivated to neutralize the virus and added to fresh EJ cells for a further 72hrs at 
370C. In the presence of supernatants from EJ cells infected with OncovexGFP no cell 
death was seen with or without 5-FC (Figure 2a). However, in the presence of 
supernatant cells exposed to both OncovexGALV/CD +5-FC, effective cell killing was 
seen (Figure 2a). Results were similar in a range of human bladder tumour cell lines, 
including RT112 cells, TCCSUP-G cells, 5637 cells, KU19-19 cells (data not shown). 
MTS assays were used to quantitate the effects of prodrug activation therapy on 
bladder tumour cells in vitro. EJ cells were the most susceptible to prodrug activation 
therapy (Figure 2b). A 55% decrease in tumour cell survival was detected on EJ cells 
at the concentration of 100µm 5-FC (Figure 2b), which decreased further to 78% at 
600µm 5-FC (P <0.000) (Figure 2b). RT112 and KU19-19 cells showed moderate 
sensitivity for OncovexGALV/CD prodrug activation therapy. At between 600-1000µm 
5-FC these cell lines showed around 70% decrease in tumour cell survival (Figure 
2b). Finally TCCSUP-G and 5637 cells showed the lowest sensitivity for this prodrug 
activation therapy, around 53% decrease in tumour cell survival at 1000µm 5-FC 
(1000µm P<0.000) (Figure 2b). From these results we concluded that five out of 
seven TCC cells were sensitive to metabolites of 5-FC after infection with 
OncovexGALV/CD (in the presence of 5-FC) (Figure 2b).  
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OncovexGALV/CD and chemotherapeutic agent Mitomycin C, show synergistic 
interaction on bladder TCC tumour cell lines, but not with Cisplatin or 
Gemcitabine.  
 
Currently the three mostly clinically used intravesical chemotherapy agents for 
bladder cancer are mitomycin C (MMC), cisplatin and gemcitabine. The effect of a 
combination of OncovexGALV/CD and chemotherapy on cytotoxicity was therefore 
assessed for significance by isobologram analysis by calculating combination index 
(CI) values (see materials and methods). Chemotherapy and OncovexGALV/CD were 
administered to cells concomitantly. We tested TCC cells including EJ, T24, 
TCCSUP-G and KU19-19. We observed synergistic cell killing with OncovexGALV/CD 
and MMC on EJ (ED50 0.77 +/- 0.05), T24 (ED50 0.65 +/- 0.07) and KU19-19 (ED50 
0.78 +/- 0.01) TCC cells (Table 1b). However, a combination of OncovexGALV/CD and 
cisplatin /gemcitabine was antagonistic on EJ, (or T24,
 or TCCSUP-G) cells at most 
ED50-90. An exception to this was OncovexGALV/CD and gemcitabine on T24 cells at 
high dose (Table 1b). This high dose synergy with OncovexGALV/CD and gemcitabine 
was not seen on two other TCC cell lines (EJ and KU19-19, Table 1b). The results 
indicate that the co-administration of OncovexGALV/CD and MMC showed a synergistic 
effect, whereas the co-administration with cisplatin or gemcitabine showed an 
antagonistic effect in vitro. 
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HSV replication is enhanced by the expression of GALV glycoprotein on TCC 
cells.  
 
To address whether GALV-related fusion affected HSV replication in TCC cells, 
OncovexGALV/CD and control OncovexGFP virus stocks were prepared on EJ cells. The 
resulting stocks were replated onto BHK cells, which do express the Pit-1 receptor 
that allows GALV-related fusion (Sommerfelt et al, 1990). The results show that 
infection of EJ cells with OncovexGALV/CD showed a log higher enhanced viral 
replication compared to control virus (Figure 3a, P=0.000). This confirms previous 
results seen in fibrosarcoma (HT1080) (Simpson et al, 2006). We predict that the 
process of fusion allows more cellular resources to be obtained which aids viral 
replication.  
 
HSV replication on TCC cells is not inhibited by 5-FC but can be inhibited by 5-
FC metabolites.  
 
The conversion of 5-FC to 5-FU results in an inhibition of host DNA replication that 
might be expected to also inhibit HSV. This was investigated on EJ cells by infecting 
them with OncovexGALV/CD at various MOI with or without 600 mM 5-FC. The 
resulting infected lysates were then titred on BHK cells and showed no significant 
difference in titre with or without 5-FC, Figure 3b. In contrast if EJ cells were 
exposed to the metabolites of 5-FC at the point of infection with OncovexGALV/CD a 
dramatic drop in viral replication was seen over 10 fold (Figure 3c, P value (moi 0.1) 
0.005). Our results suggest that primary oncolytic HSV replication is not inhibited by 
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converting 5-FC to 5-FU by Fcy::Fur in EJ cells but subsequent rounds of infection 
may be.  
 
TCC cells follow an apoptotic cell death pathway after infection with 
OncovexGALV/CD with or without 5-FC.  
 
Transfection of viral fusogenic membrane GALV in tumour cells results in non 
apoptotic death (Higuchi et al, 2000; Lin et al, 2010; Bateman et al, 2000; Linardakis 
et al, 2002). Apoptosis is triggered early in a HSV-1 infection. During the later stages 
of the virus life cycle, anti-apoptotic proteins such as ICP4, ICP6, US11, gD, and gJ 
(Nguyen et al, 2007) are produced allowing the cells to assemble viral progeny prior 
to apoptotic cell death (Nguyen et al, 2007). The expression of CD-UPRT in the 
presence of 5-FC also results in apoptotic death within tumour cells (Gopinath et al, 
2008). In our study apoptotic death was measured in EJ cells by measuring caspase 
activity. EJ cells were infected with OncovexGALV/CD or OncovexGFP with or without 
5-FC/5-FC metabolites and caspase 3 and 7 activity were measured using caspase Glo 
3/7 reagent (Promega). At the early time point (24hrs) both OncovexGALV/CD and 
OncovexGFP infection of EJ cells showed limited caspase 3 and 7 activity compared to 
cells exposed to 5-FC or 5-FC metabolites (Figure 4a). At later time points the 
caspase signal in HSV infected cells rose in comparison to cells exposed to prodrug 
therapy (Figure 4a), suggesting that the caspase assay has not picked up viral driven 
early apoptosis due to the fact that the virus has got through more than one round of 
replication at 24 hrs and that anti-apoptotic viral proteins inhibited its signal until the 
later stage of the viral life cycle. It was interesting to see that OncovexGALV/CD + 5-FC 
produced a caspase signal similar to the 5-FC metabolites, which suggests that early 
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prodrug therapy induced caspase activity as much as its later metabolites (Figure 4a). 
In addition viral anti-apoptotic proteins, failed to inhibit prodrug induced caspase 
activity (Figure 4a) and this early prodrug induced caspase activity did not inhibit 
viral replication (Figure 3b). When comparing caspase activity between the oncolytic 
HSV expressing GALV glycoprotein and the backbone virus, no difference was seen 
at the early time points (24, 48 hrs, Figure 4a), a slight increase was seen with GALV 
expression at 72hrs, but this was not statistically significant (72 hrs, Figure 4a, P= 
0.06). It was concluded that GALV glycoprotein expression did not alter caspase 
activity in infected EJ cells. 
 
Caspase inhibiter blocks OncovexGALV/CD cell death pathway in bladder TCC 
cells in vitro. In contrast a necrosis inhibiter fails to inhibit such cell death.  
To establish if OncovexGALV/CD cell death is a purely apoptotic driven process, 
infected EJ cells were exposed to Z-VAD fmk (a pan caspase inhibiter), after which 
samples were assayed for LDH, a marker for cytotoxic cell death. Results showed that 
in EJ cells infected either with OncovexGALV/CD or OncovexGFP cytotoxic cell death 
can be blocked almost totally by inhibiting the caspase cascade (Figure 4b), 
suggesting that both viruses cause cell death by an apoptotic pathway. Apoptosis is 
mediated by caspase protease activation and requires ATP (Rosser et al, 1995; 
Nicotera et al, 1998; Bernardi et al, 1999). Necrosis results from ATP depletion 
(Rosser et al, 1995; Green et al, 1998). Adding fructose to cells generates ATP 
through glycolysis, which is sufficient to inhibit necrotic cell death (Anundi et al, 
1989). To investigate this necrotic component EJ cells were infected with 
OncovexGALV/CD or OncovexGFP and incubated for 24/48 hrs. Our results indicate that 
the presence of fructose enhanced cell death rather than inhibiting it in EJ cells 
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infected with OncovexGALV/CD (and to a lesser extent in OncovexGFP) (Figure 4c) This 
suggests that the cytotoxicity was controlled by a non necrotic pathway and that the 
fructose was feeding the apoptotic pathway. This hypothesis was confirmed by the 
fact that fructose enhances cell death and can be blocked by Z-VAD fmk (Figure 4d). 
Taken as a whole this data suggests that OncovexGALV/CD cell death is a purely 
apoptotoic driven pathway rather than through necrosis/autophagy as seen during 
transfection of viral fusogenic membrane GALV (Lin et al, 2010). 
 
Treatment of a rat orthotopic bladder tumour model with OncovexGALV/CD with 
or without 5-FC.  
 
To model in vivo human superficial bladder cancer a rat orthotopic bladder tumour 
model was used that was previously described by Xiao et al, 1999. AY-27 rat bladder 
tumour (TCC) cells which were previously tested for susceptibility for HSV 
replication were used in this model. AY-27 cells were stably transfected with the 
herpesvirus entry receptor (HVEM) and a clone selected that supported infection with 
HSV. Fusion assay results showed a reduction in metabolic enzyme activity of up to 
30% (MTS assay) in AY-27 HVEM cells infected with OncovexGALV/CD compared to 
the OncovexGFP control (Supplementary Figure 1s). This is in addition to the 
cytotoxcity seen with HSV replication alone. AY-27 HVEM cells were further tested 
in our prodrug assay, which showed that OncovexGALV/CD can metabolize 5-FC within 
these cells, resulting in a decrease in metabolic enzyme activity of up to 81% (MTS 
assay) when compared to controls (Supplementary Figure 1s). To facilitate tumour 
seeding, the bladder mucosa was conditioned with an acid rinse followed by 
neutralization with alkali. After tumour seeding a high success rate of implantation 
 15 
was seen (>95%). Figure 5d shows an example of such an in vivo experiment 
(without treatment), where tumours were seeded and the bladder removed at necropsy 
after 18 days. The first three bladders showed a high tumour load (Figure 5d 1, 2 & 
3). The fourth bladder was a control in which bladder mucosa was conditioned 
(acid/alkali rinse) but no cells were seeded (Figure 5d 4). The tumour implantation 
procedure was well tolerated by the animals. To study the effects of OncovexGALV/CD 
in vivo freshly harvested AY-27 HVEM cells were installed as described above (Day 
0). The tumour bearing animals were assigned into three treated groups either 
OncovexGALV/CD+5-FC (n=10), OncovexGALV/CD +PBS (n=10) or PBS+5-FC (control 
group) (n=8). Intravesical treatment of implanted tumours was carried out with virus 
(OncovexGALV/CD, 9e7 pfu) or control PBS on Days 7, 14 and 21. Prodrug 5-FC 
(12.5mg/ml) or PBS was installed in the same manner on Days 8, 9, 15, 16, 22 and 
24 and the animals were sacrificed on Day 28. Bladders were removed and assessed 
for tumour growth. The results showed an 84.5% reduction in average tumour volume 
in the presence of both OncovexGALV/CD and prodrug when compared to control 
(P=0.001) or virus alone P=0.034) (Figure 5a). A smaller amount of tumour 
shrinkage seen with virus alone was not statistically significant when compared to 
control animals (46.4% tumour reduction), (P=0.13) (Figure 5a). The bladders were 
weighed and showed a trend of lower bladder weight after treatment with both agents 
(Figure 5c). On average the animals treated with OncovexGALV/CD +5-FC were 11.5g 
heavier than controls, suggesting that they were in a healthy condition compared to 
controls (Figure 5b). The results strongly suggest that a combination of oncolysis, 
prodrug activation and fusogenic glycoprotein therapy offers an opportunity for 
improved tumour control within the bladder. 
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Computed microtomography (microCT) imaging of an orthotopic bladder 
tumour model, during treatment with OncovexGALV/CD +5-FC.  
 
For the orthotopic in vivo experiments there was no way of establishing how much 
tumour was present until autopsy. An attempt was made to quantify tumour load by 
HVEM qPCR in urine of implanted rats. The results showed no reliable signal was 
detected that correlated to the amount of tumour present at autopsy (data not shown). 
As a result tumour growth was evaluated by non invasive imaging using IVIS, by 
inserting the insect luciferase gene into AY-27 HVEM cells.  When these cells were 
assessed in vivo (Fischer F344 flank model), a luciferase signal was detected initially 
but faded due to regression of the tumour (data not shown). To overcome this problem 
microCT was used with the aim of establishing the feasibility of imaging the tumours 
non-invasively whilst they were growing and the process of oncolysis/prodrug 
activation within the bladder of Fischer F344 rats. These rats were implanted with 
freshly harvested AY-27 HVEM cells. On day 5 (Figure 6) after implantation, a 
catheter was inserted into the bladder via the urethra with the use of an 18-gauge 
plastic intravenous cannula (BD Venflon Pro) which had been prefilled with iodine 
contrast (50% iodine contrast in PBS). The bladder was filled with iodine contrast 
solution and then the animal was scanned on a SkyScan1076 in-vivo micro-CT (Scan 
parameter: 35mcm per slice, 68kV, range of detector motion 192 degrees, 0.5mm 
aluminium filter). Further scans were carried out on day 11, 15, 22 and 29 using the 
same method (Figure 6). Intravesical treatment of implanted tumours was carried out 
with virus (OncovexGALV/CD, 9e7 pfu) (or control PBS) on days 6, 12 and 18. Prodrug 
5-FC (12.5mg/ml) was installed in the same manner on days 7, 8, 13, 14, 19 and 20 
and the animals were sacrificed on day 29. Tumours were observed in animal A, 
 17 
which had received no virus treatment (PBS) + 5-FC. This animal can be described as 
having disease progression, which filled the bladder with tumour over the course of 
the experiment (Figure 6). The presence of a large amount of tumours was confirmed 
by histology using H&E stain (Figure 5e i). The tumour was also shown to be 
proliferating using Ki67 staining (Figure 5f i). Animals B & F received 
OncovexGALV/CD +5-FC treatment as described above. Animal B had similar initial 
tumour load to animal A and showed a complete response of pedunculated 
intraluminal disease (Figure 6). Histology (H&E stain) on this animal confirmed that 
almost no tumour was presences after treatment (Figure 5e ii). In the only small area 
of disease identified in animal B no proliferating tumour cells were detected by Ki67 
staining confirming a pathological complete response. Animal F had a much higher 
initial tumour load than both A or B at the start point of treatment, but still showed a 
partial response in intraluminal pedunculated disease (Figure 6). The results clearly 
show that it is possible to visualize the growth of tumours and the process of 
oncolysis/prodrug activation in an orthotopic bladder tumour model.  
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Discussion 
 
Surgery, BCG and chemotherapy dramatically slow the progress of bladder cancer, 
but do not eradicate the disease totally (Sylvester et al, 2006). BCG therapy is the 
reference standard non-surgical treatment for high-risk non muscle invasive bladder 
cancer but is associated with relatively high morbidity, with up to 25% of patients 
failing to complete a full maintenance course. Clearly there is a need to develop new 
treatment strategies for bladder cancer, particularly for high-risk superficial tumours 
with BCG treatment failure and muscle invasive cancer.  
 
In our study we have shown that this viral based triple therapy offers a novel approach 
to intravesical treatment of bladder cancer. Our choice of an oncolytic HSV, based on 
experience with OncovexGALV/CD, has been found to be effective in treating various 
experimental cancers while maintaining an excellent safety profile (Simpson et al, 
2006; Price et al, 2010; Wong et al, 2010).  
 
All human bladder tumour cell lines tested (in vitro) were susceptible to HSV 
oncolysis and showed enhanced tumour cell killing with either fusion or prodrug 
therapy (or both) when infected with OncovexGALV/CD virus. Fusion therapy could 
enhance HSV oncolysis by decreasing tumour TCC cell survival by up to 54%. 
Prodrug therapy from OncovexGALV/CD, also killed (bystander effect) uninfected TCC 
by up to 78%. A synergistic interaction was detected between OncovexGALV/CD and 
the chemotherapy agent MMC but not Cisplatin and Gemcitabine. To study the effect 
of OncovexGALV/CD in vivo we further developed an orthotopic rat bladder model and 
confirmed safety, efficacy, and ease of delivery of oncolytic viral therapy for 
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experimental treatment of bladder cancer. OncovexGALV/CD virus, when administered 
with prodrug weekly for 3 weeks by intravesical instillation, was clearly more 
effective than control or virus alone at reducing tumour burden (84.5% reduction, 
P=0.001). To evaluate the in vivo orthotopic tumour growth and then oncolysis, we 
tried non-invasive imaging including IVIS and CT scanning. Using intravesical iodine 
contrast and CT scanning we were able to visualize the growth of tumours and 
oncolysis following OncovexGALV/CD treatment. 
 
A range of viral non-replicating vectors and oncolytic viruses have been studied in 
both mouse and rat orthotopic bladder tumour models. Non-replicating vectors such 
as lentivirus (Kikuchi et al, 2004), adenovirus (Werthman et al, 1996; Sutton et al, 
2000) and poxviruses (Fodor et al, 2005) have shown strong therapeutic gene 
expression in bladder cancer including endostatin (Shichinohe et al, 2001) and p53 
Ruifa et al, 2006). Oncolytic viruses such as retroviral (RCR) vectors (Kikuchi et al, 
2007), adenovirus (Wang et al, 2006), VSV (Hadaschik et al, 2008), reovirus (Hanel 
et al, 2004), vaccinia virus (Fodor et al, 2005) and HSV-1 (Cozzi et al, 2001) offer 
bladder tumour selective killing due to viral replication and even stronger therapeutic 
gene expression due to multiple rounds of replication and promoter up-regulation 
(Hadaschik et al, 2008). These viral orthotopic bladder studies have shown some 
efficacy, but only a few of these viral vectors have gone on to clinical trials. Those 
that have include adenovirus (Kuball et al, 2002; Pagliaro et al, 2003; Malmstrom et 
al, 2010) and vaccinia virus (Gomella et al, (2001). Strong gene transfer (WT p53, 
CD40L) has been seen using non replicating adenovirus in patients biopsies, but only 
one clinical response was seen in these early I/IIa trials (Kuball et al, 2002; Pagliaro et 
al, 2003; Malmstrom et al, 2010). In contrast an oncolytic adenovirus expressing GM-
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CSF (in combination with BCG) showed a response rate of 46% as assessed by 
cytoscopy and urine cytology or biopsy (McKiernan et al, 2009) Further studies have 
shown 3 out of 4 patients treated with an oncolytic vaccinia virus have been shown to 
be disease free after 4 years (McKiernan et al, 2009). HSV-1, like vaccinia, is a large 
DNA virus, which can be easily manipulated to allow tumour selective virus 
replication (MacLean, 1991; Martuza et al, 1991, Rampling et al, 2000) and allows 
insertion of therapeutic genes of up to 30 kb (Roizman at al 1985). Oncolytic HSV 
can infect a broad range of human tumour cell types. It is a highly lytic virus, 
resulting in tumour cell death, but does not integrate into the host genome avoiding 
the possibility of activating proto-oncogenes. 
 
We refined an existing rat orthotopic bladder tumour model to evaluate the efficacy of 
the OncovexGALV/CD virus with or without 5-FC. Advantages of a rat versus a 
mouse model include its size and evidence that  the rat model may represent the  
human disease processes better than the mouse equivalent (Oyasu,1995). In these 
models, the traditional endpoints of tumour size are not appropriate as the evolving 
intravesical tumour may block both ureters and cause urinary obstruction and renal 
failure. We therefore sought to establish a robust non-invasive method of monitoring 
response to intravesical therapy. Other assessment modalities have been used 
including urine cytology (Gronlund-Pakkanen et al, 2003), ultrasound (Rooks et al, 
2001) 45], MRI (Mazurchuk et al, 1997), qPCR (Wang et al, 2006) and 
bioluminescence imaging (Ray, 2007). We were able to closely monitor evolving 
tumour and response to treatment by CT in animals with high and low tumour 
burdens.  
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In conclusion, we found OncovexGALV/CD to be effective in vitro and in treating an 
orthotopic rat bladder cancer. A version of this virus expressing GM-CSF has shown 
promising results in Phase I and II (Hu et al, 2006, Senzer et al, 2009) with limited 
toxicity to patients and is currently in Phase III clinical trials in melanoma and head 
and neck cancer. Our results suggest that OncovexGALV/CD (+ 5-FC) intravesical 
therapy should be considered for human application. 
 
Statistics.  
 
The values of the experiments were presented as the mean ± standard deviation (or 
standard error) and analysis of variance was measured using unpaired Student's t-test. 
Statistical significance was determined at a P value less than 0.05. 
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Figure 1 Fusogenic glycoprotein cytotoxic killing of bladder TCC cells. 
 
 EJ, T24 VMCUB-I and 5637 cells were infected with OncovexGFP or 
OncoVexGALV/CD at various MOIs and incubated at 37°C/5% CO2 for 48 hours, then 
assayed by Crystal Violet staining a) or MTS assay b) (Promega). Average cell 
survival was calculated as a percentage compared to untreated cells (Unpaired student 
t-test comparing GFP Vs GALV/CD + or - 5-FC P values: EJ (MOI 10 P<0.000, MOI 
1 P<0.000), T24 (MOI 0.1 P<0.000, 0.01 P<0.000), VMCUMB-I (MOI 0.1 P<0.000, 
0.01 P<0.000), 5637 (MOI 0.1 P<0.000, 0.01 P<0.000). 
 
Figure 2 Prodrug activation in TCC cells infected OncovexGALV/CD.  
 
EJ, RT112, TCCSUP-G, 5637 and KU19-19 cells were infected with OncovexGFP and 
OncovexGALV/CD at MOI of 0.1 and no virus control. After 30 minutes at 37°C/5% 
CO2, the virus was removed, and 1ml of FGM containing 5-FC (C4H4FN2O; Sigma) at 
different concentrations (0-1400 µmol/L) was added and incubated for 48 hours at 
37°C/5% CO2. The cell supernatants were then heat inactivated and added to 1 x 104 
fresh target cells and incubated at 37°C/5% CO2 for 72 hours and assayed by fixing 
and staining with glutaraldehyde/crystal violet (a) or MTS assay (Promega) (b). 
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Average cell survival was calculated as a percentage compared to untreated cells. 
(Unpaired student t-test comparing GALV/CD + or - 5-FC P values: EJ (300 µm 
P<0.000, 600 µm P <0.000), RT112 (800µm P<0.000, 1000µm P<0.000), TCCSUP-
G 1200µm P<0.000, 1400µm P<0.000), 5637 800µm P<0.000, 1000µm P=<0.000), 
KU19-19 (800µm P<0.000, 1000µm P=<0.000). 
 
Table 1 a) Summary of oncolysis, viral glycoprotein therapy and prodrug 
activation data on human bladder TCC cells. b) The interaction of oncolytic 
HSV-1 with chemo agents on human bladder TCC cells.  
 
The effect of the combination of OncovexGALV/CD and chemotherapy on cell 
proliferation was assessed by calculating combination index (CI) values using 
CalcuSyn software (Biosoft). Derived from the median-effect principle of Chou and 
Talalay, the CI provides a quantitative measure of the degree of interaction between 
two or more agents. A CI of 1 denotes an additive interaction, >1 antagonism, and <1 
synergy. Experiments were done as described for the in vitro survival assay using 4, 2, 
1, 0.5, and 0.25 times the calculated ED50 of each agent in a constant ratio 
checkerboard design. 
 
Figure 3 Oncolytic HSV viral replication in the presence of viral glycoprotein, 5-
FC and metabolites of 5-FC.  
 
a) EJ cells were infected at various MOI (0.001 0.0001) with either OncovexGFP or 
OncovexGALV/CD and incubated at 37°C for 48hrs. Unpaired student t-test comparing 
GFP vs GALV/CD P value (moi 0.001) 0.000 (moi 0.0001) 0.0002. b) EJ cells were 
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infected at various MOIs (0.1, 0.01. 0.001) with OncovexGALV/CD in the presence or 
absence of 5-FC and incubated at 37°C for 48hrs. + or – 5-FC P value (moi 0.1) 0.03 
(moi 0.01) 0.414 (moi 0.001) 0.075. c) EJ cells were infected at various MOIs (0.1, 
0.01. 0.001) with OncovexGALV/CD in the presence or absence of metabolites of 5-FC 
and incubated at 37°C for 48hrs. The resulting virus stocks were titred on BHK cells 
using a standard plaque assay + or – metabolites of 5-FC P value (moi 0.1) 0.005 
(moi 0.01) 0.004(moi 0.001) 0.0001. 
 
Figure 4 Bladder TCC cells follow apoptotic pathway after infection with 
OncovexGALV/CD. 
 
 a) EJ cells were infected with OncovexGFP or OncovexGALV/CD (MOI 1) with or 
without 5-FC (600uM) or its metabolites for 24, 48 and 72hrs. Caspase activity was 
detected using Caspase Glo 3/7 reagent (Promega). Unpaired student t-test comparing 
GFP vs GALV/CD P value 24hrs 0.8919 48hrs 0.2596 72hrs 0.061. b) EJ cells were 
infected OncovexGALV/CD or OncovexGFP at MOIs of 1, 0.1 and then incubated with 
and without 50uM Z-VAD-FMK (sigma) for 48/72hrs. After which the supernatant of 
the samples were assayed for lactate dehydrogenase activity (LDH) a marker of 
cytotoxic cell death (Roche). c) EJ cells were infected with OncovexGALV/CD or 
OncovexGFP at MOIs of 1, 0.1 and then incubated with and without 20mM Fructose 
and incubated for 48/72hrs at 370C. LDH assays were carried out on sample 
supernatant. d) EJ cells were infected with OncovexGALV/CD at MOIs of 1, 0.1 and 
then incubated with either 50uM Z-VAD-FMK or 20mM Fructose or both and 
incubated/assayed as above. (Unpaired student t-test comparing P valve Onc vs Onc 
ZVAD, 48Hrs MOI 1 P>0.0000, MOI 0.1 P 0.0127, 72Hrs MOI 1 P>0.0000, MOI 
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0.1 P 0.000. GALV vs GALV ZVAD 48Hrs MOI 1 P>0.0000, MOI 0.1 P>0.0000, 
72Hrs MOI 1 P>0.0001, MOI 0.1 P>0.0000. Onc vs Onc Fru, 48Hrs MOI 1 
P0.0078, MOI 0.1 P 0.0032, 72Hrs MOI 1 0.0051, MOI 0.1 0.3229, GALV vs 
GALV Fru  48Hrs MOI 1 P>0.0015, MOI 0.1 P>0.0001, 72Hrs MOI 1 0.0595, MOI 
0.1 0.0148. 
 
Figure 5 Treatment of a rat orthotopic bladder tumour model with 
OncovexGALV/CD +5-FC.  
 
AY-27 HVEM cells were implanted into the bladders of female Fischer F344 rats at 
day 0. The tumour bearing animals were assigned into three treatment groups either 
OncovexGALV/CD+5-FC (n=10), OncovexGALV/CD +PBS (n=10) or PBS+5-FC (control 
group) (n=8). Intravesical treatment of implanted tumours was carried out with virus 
(OncovexGALV/CD, 9e7 pfu) or Control PBS on Days 7, 14 and 21. Prodrug 5-FC 
(12.5mg/ml) or PBS was installed in the same manner on Days 8, 9, 15, 16, 22 and 
24 and the animals were sacrificed on Day 28. Their bladders were removed and 
assessed for tumour abundance. The harvested bladders were weighed, then opened 
up and the bladder surface which macroscopically contained tumour was measured 
with a caliper. Average tumour volume was calculated by measuring length x width/2. 
a) Average tumour volume b) Average body weight c) Average bladder weight 
(Unpaired student t-test comparing tumour volume PBS vs GALV/CD +5-FC 
P=0.001, PBS GALV/CD- 5-FC vs GALV/CD +5-FC P=0.034, PBS vs GALV/CD -
5-FC P=0.13. d) Bladder seeded with tumour cells (no treatment) and removed at 
necropsy after 18 days (1, 2 & 3). Bladder 4 was a control in which bladder mucosa 
was conditioned (acid/alkali rinse) but no cells were seeded. e) H&E stain of sections 
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from bladder from animals A&B. f) Ki67 stain (brown) of sections from bladder from 
animals A (i)& B (iii). No primary antibody control sections from animals A (ii) & B 
(iv). 
 
Figure 6 Computed Tomography imaging of an orthotopic bladder tumour 
model during treatment with OncovexGALV/CD + 5-FC.  
 
Intravesical treatment of implanted tumours was carried out with virus 
(OncovexGALV/CD, 9e7 pfu) (or Control PBS) on days 6, 12 and 18. Prodrug 5-FC 
(12.5mg/ml) was installed in the same manner on days 7, 8, 13, 14, 19 and 20 and the 
animals were sacrificed on day 29. During the experiment computed tomography 
imaging was carried out on days 5, 11, 15, 22 and 29. 
 
Supplementary Figure 1 Fusogenic and Prodrug activation on TCC cells infected 
OncovexGALV/CD (+/- 5-FC). 
 
 a) AY-27 HVEM cells were infected with OncovexGFP or OncoVexGALV/CD at various 
MOIs and incubated at 37°C/5% CO2 for 48 hours, then assayed by MTS assay 
(Promega). b) AY-27 HVEM cells were infected with OncovexGFP and 
OncovexGALV/CD at MOI of 0.1 and no virus control. After 30 minutes at 37°C/5% 
CO2, the virus was removed, and 1ml of FGM containing 5-FC (C4H4FN2O; Sigma) at 
different concentrations (0-300 µmol/L) was added and incubated for 48 hours at 
37°C/5% CO2. The cell supernatants were then heat inactivated and added to 1 x 104 
fresh target cells and incubated at 37°C/5% CO2 for 72 hours and assayed by MTS 
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assay (Promega). Average cell survival was calculated as a percentage compared to 
untreated cells. 
 
